| 1 |
Rho YH, Zhu Y, Choi HK. The Epidemiology of Uric Acid and Fructose [J]. Semin Nephrol, 2011, 31(5): 410-419.
|
| 2 |
中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J]. 中华内分泌代谢杂志, 2013, 29(11): 913-920.
|
| 3 |
Soltani Z, Rasheed K, Kapusta DR, et al. Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal? [J]. Curr Hypertens Rep, 2013, 15(3): 175-181.
|
| 4 |
Techatraisak K, Kongkaew T. The association of hyperuricemia and metabolic syndrome in Thai postmenopausal women [J]. Climacteric, 2017, 20(6): 552-557.
|
| 5 |
Liu PJ, Ma F, Lou HP, et al. Relationship between serum uric acid levels and metabolic syndrome in Chinese postmenopausal women [J]. Climacteric, 2014, 17(2): 148-154.
|
| 6 |
Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies [J]. BMC Nephrol, 2014, 15(1): 122.
|
| 7 |
Xu X, Hu J, Song N, et al. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis [J]. BMC Nephrol, 2017, 18(1): 27.
|
| 8 |
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008 [J]. Arthritis Rheum, 2011, 63(10): 3136-3141.
|
| 9 |
Liu H, Zhang XM, Wang YL, et al. Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling [J]. J Nephrol, 2014, 27(6): 653-658.
|
| 10 |
Rui L, Cheng H, Di W, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis [J]. Biomed Res Int, 2015, 2015(15, supplement): 1-12.
|
| 11 |
Benn CL, Dua P, Gurrell R, et al. Physiology of Hyperuricemia and Urate-Lowering Treatments [J]. Front Med (Lausanne), 2018, 5: 160.
|
| 12 |
B Á, Alonso-Valdivielso JL. Hyperuricemia and gout; the role of diet [J]. Nutr Hosp, 2014, 29(4): 760-770.
|
| 13 |
Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney [J]. Pediatr Nephrol, 2014, 29(6): 999-1008.
|
| 14 |
Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity [J]. Diabetes, 2013, 62(10): 3307-3315.
|
| 15 |
Anzai N, Enomoto A, Endou H. Renal urate handling: Clinical relevance of recent advances [J]. Curr Rheumatol Rep, 2005, 7(3): 227-234.
|
| 16 |
黄胜华. 高尿酸血症及其肾损伤的研究进展 [J]. 医学研究生学报, 2010, 23(11): 1217-1221.
|
| 17 |
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379(9818): 815-822.
|
| 18 |
Khadka M, Pantha B, Karki L. Correlation of Uric Acid with Glomerular Filtration Rate in Chronic Kidney Disease [J]. JNMA J Nepal Med Assoc, 2018, 56(212): 724-727.
|
| 19 |
Zhu Y, Pandya BJ, Choi HK. Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008 [J]. Am J Med, 2012, 125(7): 679-687.
|
| 20 |
Kim IY, Lee DW, Lee SB, et al. The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship [J]. Biomed Res Int, 2014, 2014(2): 638732.
|
| 21 |
Filiopoulos V, Hadjiyannakos D, Vlassopoulos D. New insights into uric acid effects on the progression and prognosis of chronic kidney disease [J]. Ren Fail, 2012, 34(4): 510-520.
|
| 22 |
Chou YC, Kuan JC, Yang T, et al. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements [J]. J Nephrol, 2015, 28(4): 457-462.
|
| 23 |
鄂静，郑亚莉，曹丽, 等. 高尿酸血症引起慢性肾脏病的Meta分析 [J]. 宁夏医学杂志, 2015, 37(3): 229-231.
|
| 24 |
张淑艳. 高尿酸血症肾病的临床特点及诊断 [J]. 中国医师进修杂志, 2004(s1): 159-160.
|
| 25 |
李娟. 高尿酸血症肾病的临床表现与治疗现状 [J]. 临床合理用药杂志, 2012, 5(28): 120-121.
|
| 26 |
Kumari A, Dokwal S, Mittal P, et al. An Increase Incidence in Uric Acid Nephrolithiasis: Changing Patterns [J]. J Clin Diagn Res, 2016, 10(7): BC01-3.
|
| 27 |
Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis [J]. Urol Clin North Am, 2007, 34(3): 335-346.
|
| 28 |
Abou-Elela A. Epidemiology, Pathophysiology And Management Of Uric Acid Urolithiasis: A Narrative Review [J]. J Adv Res, 2017, 8(5): 513-527.
|
| 29 |
Kunitoshi I, Chiho I, Kozen K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan [J]. Hypertens Res, 2013, 36(7): 650-654.
|
| 30 |
Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers [J]. J Epidemiol, 2000, 10(6): 403-409.
|
| 31 |
Hisashi Y. Japanese guideline for the management of hyperuricemia and gout: second edition [J]. Nucleosides Nucleotides Nucleic Acids, 2011, 30(12): 1018-1029.
|
| 32 |
Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia [J]. Arthritis Care Res, 2012, 64(10): 1431-1446.
|
| 33 |
中国慢性肾脏病患者合并高尿酸血症诊治共识专家组. 中国慢性肾脏病患者合并高尿酸血症诊治专家共识 [J]. 中华肾脏病杂志, 2017, 33(6): 463-469.
|
| 34 |
Choi HK, Atkinson K, Karlson EW, et al. Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men [J]. N Engl J Med, 2004, 350(11): 1093-1103.
|
| 35 |
Ma L, Wei L, Chen H, et al. Influence of urate-lowering therapies on renal handling of uric acid [J]. Clin Rheumatol, 2016, 35(1): 133-141.
|
| 36 |
Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis [J]. Arthritis Care Res (Hoboken), 2012, 64(10): 1447-1461.
|
| 37 |
Wichittra T, Thawinee J, Pei C, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population [J]. Pharmacogenet Genomics, 2009, 19(9): 704-709.
|
| 38 |
Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk [J]. Nat Rev Rheumatol, 2016, 12(4): 235-242.
|
| 39 |
Hosoya T, Kimura K, Itoh S, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study [J]. Trials, 2014, 15(1): 26.
|
| 40 |
何志红，易建伟，袁峰, 等. 非布司他治疗尿酸性肾病的临床疗效观察 [J]. 现代医院, 2016, 16(9): 1260-1262.
|
| 41 |
Liu CT, Chen CY, Hsu CY, et al. Risk of Febuxostat-Associated Myopathy in Patients with CKD [J]. Clin J Am Soc Nephrol, 2017, 12(5): 744-750.
|
| 42 |
White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout [J]. N Engl J Med, 2018, 378(13): 1200-1210.
|
| 43 |
Kawamorita Y, Shiraishi T, Tamura Y, et al. Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats [J]. Physiol Rep, 2017, 5(15): e13358.
|
| 44 |
Mizukoshi T, Kato S, Ando M, et al. Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial [J]. Nephrology (Carlton), 2018, 23(11): 1023-1030.
|
| 45 |
Mende C. Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy [J]. Adv Ther, 2015, 32(12): 1177-1191.
|
| 46 |
Ramasamy SN, Korb-Wells CS, Kannangara DRW, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012 [J]. Drug Saf, 2013, 36(10): 953-980.
|
| 47 |
Guttmann A, Krasnokutsky S, Pillinger MH, et al. Pegloticase in gout treatment-safety issues, latest evidence and clinical considerations [J]. Ther Adv Drug Saf, 2017, 8(12): 379-388.
|
| 48 |
Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials [J]. JAMA, 2011, 306(7): 711-720.
|
| 49 |
Howard SC, Jones DP, Pui CH. Tumor Lysis Syndrome [J].N Engl J Med, 2014, 364(19): 1844-1854.
|
| 50 |
Yu F, Feifei W, Yakun L, et al. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis [J]. J Hypertens, 2015, 33(4): 681-689.
|
| 51 |
Li-Jun LI, Chen H, Ren JY, et al. Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia [J]. Beijing Da Xue Xue Bao Yi Xue Ban, 2009, 41(5): 541-544.
|
| 52 |
Derosa G, Maffioli P, Reiner Ž, et al. Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis [J]. Drugs, 2016, 76(9): 947-956.
|
| 53 |
Ma Z, Long L, Liu J, et al. Montmorillonite adsorbs uric acid and increases the excretion of uric acid from the intestinal tract in mice [J]. J Pharm Pharmacol, 2009, 61(11): 1499-1504.
|
| 54 |
Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer Decreases Serum Uric Acid Concentration through Adsorption of Uric Acid in Maintenance Hemodialysis Patients [J]. Intern Med, 2009, 48(6): 415-420.
|